Rucaparib CAS 283173-50-2

Product Description:

Product Name: Rucaparib CAS NO: 283173-50-2

Synonyms:

6H-Pyrrolo[4,3,2-ef][2]benzazepin-6-one,8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl];

UNII-8237F3U7EH;

8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-azepino[5,4,3-cd]indol-6-one;

Chemical & Physical Properties:

Appearance: Yellow solid

Assay :≥99.0%

Density: 1.281 g/cm3

Boiling Point: 625.248℃ at 760 mmHg

Flash Point: 331.938℃

Storage temp.: Keep in dark place,Sealed in dry,2-8℃

Vapour Pressure: 0.0±1.8 mmHg at 25℃

Index of Refraction: 1.649

Safety Information:

HS Code: 2933990090

Rucaparib (AG 014699) is a PARP inhibitor being investigated as a potential anti-cancer agent. Rucaparib is the first-in-class clinical candidate targeting the DNA repair enzyme poly-ADPribose polymerase-1 (PARP-1), and was first synthesised as part of a collaboration between scientists working in Northern Institute of Cancer Research and Medical School of Newcastle University, alongside Agouron Pharmaceuticals (San Diego). It is being developed by Clovis Oncology.

Rucaparib inhibits "the contraction of isolated vascular smooth muscle, including that from the tumours of cancer patients. It also reduces the migration of some cancer and normal cells in culture."; It can be taken orally in tablet form.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.